INTRODUCTION {#s1}
============

Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and lungs to noxious particles or gases \[[@R1]\]. Exposure to cigarette smoke and other noxious particles is an important risk factor for COPD. Smoking is also a risk factor for lung cancer. COPD patients have a high incidence of smoking and higher incidence to develop lung cancer than non-COPD smokers \[[@R2], [@R3]\]. The risk of lung cancer in COPD patients owing to the COPD itself vs. smoking has been investigated in the past. The evidence suggests that COPD is an independent risk factor for lung cancer \[[@R4]--[@R6]\]. Studies have shown that patients with mild or moderate/severe obstructive pulmonary disease have a significantly higher incidence of lung cancer than non-COPD patients after adjusting for factors related to smoking \[[@R4]\], and similar results have been reported in other studies after matching or adjusting for age, sex, and smoking status \[[@R5], [@R6]\]. Additionally, there is a positive relationship between COPD severity and the development of lung cancer \[[@R7]\].

The Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) recommends that patients with mild to moderate COPD be predominantly treated with inhaled bronchodilators. Inhaled corticosteroids (ICS) are suggested as a treatment for patients with severe and very severe COPD, especially those with repeated exacerbations \[[@R1]\] and a post-bronchodilator predicted forced expiratory volume in the first second (FEV1) \< 50%, with one or more acute exacerbations per year or more than one hospitalization per year \[[@R8]\]. Regular ICS treatment improves symptoms and quality of life, and decreases the frequency of exacerbations \[[@R9]\].

Chronic inflammation may be a causative factor in a variety of cancers. Generally, the longer the inflammation lasts, the higher the risk of cancer. Long-term exposure to inflammatory mediators results in increased cell proliferation, mutagenesis, oncogene activation, and angiogenesis. The end result is a loss of normal growth-controlled cell proliferation \[[@R10], [@R11]\]. The mechanisms by which COPD patients develop lung cancer are not well established. There is growing evidence that the two diseases have common causes, such as the same underlying tendency, underlying genetic predisposition, telomere shortening, mitochondrial dysfunction, or premature aging \[[@R12]\]. COPD may be a driving factor in lung cancer as it can increase oxidative stress and the result in DNA damage, thereby increasing long-term exposure to proinflammatory cytokines, inhibiting DNA repair mechanisms, and leading to increased cell proliferation \[[@R12]\]. Moreover, lung cancer develops in a host environment in which the dysregulated inflammatory response may promote tumor progression. Chronic inflammation in COPD via the aforementioned mechanisms may drive lung cancer development; thus, the use of anti-inflammatory drugs as anti-cancer treatment is gaining interest in the field. Preclinical studies have also demonstrated that glucocorticoids inhibit the growth of lung cancer cells \[[@R13], [@R14]\]. ICS have been shown to regulate the production of prostaglandin E2 via cyclooxygenase-2 (COX-2) \[[@R15]\], as well as inhibiting proto-oncogenes in smokers \[[@R16]\]. In addition, ICS have been shown to reduce local and systemic inflammation among patients with COPD \[[@R17]--[@R19]\]. Another prospective observational study demonstrated that a high ICS dose is correlated with a decreased risk of lung cancer \[[@R20]\]. However, there are many conflicting ideas in the literature about the role of ICS in the prevention of lung cancer \[[@R20]--[@R27]\]. Taiwan\'s National Health Insurance (NHI) database may provide a larger population and longer follow-up interval data than previous studies. Therefore, we conducted a nationwide population-based cohort study to investigate whether the use of ICS reduces the incidence of lung cancer.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

We enrolled 13,686 female patients with COPD in the present study (Figure [1](#F1){ref-type="fig"}). Demographic characteristics of the patients are listed in Table [1](#T1){ref-type="table"}. Among this population, 8,977 patients (65.59%) were older than 60 years, and 940 of these patients had been administered ICS; 7,953 patients (58.11%) had an income of less than 15,847 New Taiwan Dollar (NTD) per month, and 941 of these patients had been administered ICS; and 10,226 patients (74.72%) had hypertension, and 1,203 of these patients had been administered ICS. Oral steroid use was prescribed in 1,683 patients (12.3%). Of 1,290 ICS users, 285 (22.09%) had ever been prescribed an oral steroid. Oral steroid use was significantly different between ICS users and non-users (22.09% vs. 11.28%, *P \<* 0.001).

![Flow chart for patient selection\
Note : This is a retrospective, population-based study in which we extracted data of female patients newly diagnosed with COPD between 1997 and 2009 from the Taiwan\'s National Health Insurance database (ICD-9-CM 491, 492, 496). Patients with COPD were defined by the presence of two or more diagnostic codes for COPD within 12 months. Patients were excluded if they were \< 40 years, if lung cancer had been diagnosed prior to the diagnosis of COPD, or if the patient had cases of asthma (ICD-9 CM code 493.X) before the index date. The enrolled patients (*n* = 13,686) were followed-up until 2011, and the incidence of lung cancer was determined. Abbreviations: COPD: chronic obstructive pulmonary disease; ICD-9-CM, International Classification of Diseases, Ninth Revision--Clinical Modification.](oncotarget-08-29711-g001){#F1}

###### Demographic characteristics of patients in the cohort

  Variables                All patients   Patient with ICS use   Without ICS use   *p*-value       
  ------------------------ -------------- ---------------------- ----------------- --------------- ----------
  Follow_up (years)        9.78 ± 3.32    10.75 ± 2.91           9.68 ± 3.35       \< .0001        
  Age                                                                                              
  ≥ 40\~\< 50              2077           15.18                  178 (13.80)       1899 (15.32)    0.0672
  ≥ 50\~\< 60              2632           19.23                  268 (20.78)       2364 (19.07)    
  ≥ 60                     8977           65.59                  844 (65.43)       8133 (65.61)    
  Income (NTD)                                                                                     
  \< 15840                 7953           58.11                  794 (61.55)       7159 (57.75)    0.1811
  ≥ 15840\~\< 21900        1659           12.12                  141 (10.93)       1518 (12.25)    
  ≥ 21900\~\< 34800        3169           23.16                  273 (21.16)       2896 (23.36)    
  ≥ 34800                  905            6.61                   82 (6.36)         823 (6.64)      
  Oral steroid                                                                                     
  No use                   12003          87.70                  1005 (77.91)      10998 (88.72)   \< .0001
  Any use                  1683           12.30                  285 (22.09)       1398 (11.28)    
  Medical disease                                                                                  
  Pulmonary tuberculosis   983            7.18                   158 (12.25)       825 (6.66)      \< .0001
  Bacterial pneumonia      1161           8.48                   225 (17.44)       936 (7.55)      \< .0001
  Bronchiectasis           1270           9.28                   259 (20.08)       1011 (8.16)     \< .0001
  Pulmonary Fibrosis       155            1.13                   44 (3.41)         111 (0.90)      \< .0001
  Hypertension             10226          74.72                  1038 (80.47)      9188 (74.12)    \< .0001
  Diabetes mellitus        6062           44.29                  683 (52.95)       683 (43.39)     \< .0001

Abbreviations: NTD: New Taiwan Dollar.

Protective effects of ICS on lung cancer in patients with chronic obstructive pulmonary disease {#s2_2}
-----------------------------------------------------------------------------------------------

The time to lung cancer diagnosis after initial diagnosis of COPD was significantly different between ICS users and non-users (10.75 vs. 9.68 years, *P \<* 0.001; Table [1](#T1){ref-type="table"}). Lung cancer incidence with regard to variable ICS dose was determined adjusting for age, income, and comorbidities by Cox regression analyses (Table [2](#T2){ref-type="table"}). The cumulative dose was calculated as duration of ICS use × dosage of ICS. A therapeutic dose of 39.48 mg ICS was used as the median value of the cumulative dose in each patient. The incidence rate of lung cancer per 100,000 person-years was 235.92 among ICS non-users and 158.67 among ICS users \[ICS non-users, HR = 1; ICS users crude HR = 0.70 (95% confidence interval {CI}: 0.46--1.09)\]. After adjusting for age, income, and comorbidities, ICS cumulative dose \> 39.48 mg was associated with a lower risk of lung cancer \[no ICS use, HR = 1.0; ICS use \> 0 mg but ≤ 39.48 mg, HR = 0.95 (95% CI: 0.67--1.60); ICS use \> 39.48 mg, HR = 0.45 (95% CI: 0.21--0.96)\] by Model II Cox regression analyses (Table [2](#T2){ref-type="table"}). The cumulative lung cancer probability among patients with cumulative ICS use \> 39.48 mg compared with non-users was significant (*P* = 0.0222) (Figure [2](#F2){ref-type="fig"}). Model I Cox regression analyses showed that there was no significant difference between without ICS users and any ICS users adjusted by age, income, and comorbidities (Table [2](#T2){ref-type="table"}). Model III Cox regression analyses showed the dose-duration-day (DDD) was not associated with the incidence of lung cancer adjusted by age, income, and comorbidities (Table [2](#T2){ref-type="table"}).

###### Multivariate analysis of lung cancer incidence in variable ICS dose adjusted for age, income, and comorbidities by cox regression mode

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                              No. of patients   No. of person-years   No. of patients with lung ca   Incident Rate\               Crude HR\           Mode I Multivariate-Adjusted HR (95% CI)   Mode II Multivariate-Adjusted HR (95% CI)   Mode III Multivariate-Adjusted HR (95% CI)
                                                                                                     (per 100,000 person-years)   (95% CI)                                                                                                   
  --------------------------- ----------------- --------------------- ------------------------------ ---------------------------- ------------------- ------------------------------------------ ------------------------------------------- --------------------------------------------
  Age                                                                                                                                                                                                                                        

   ≥ 40\~\< 50                2077              20435.73              15                             73.40                        1.00                1.00                                       1.00                                        1.00

   ≥ 50\~\< 60                2632              25993.40              26                             100.03                       1.37 (0.72\~2.58)   1.52 (0.79\~2.91)                          1.52 (0.79\~2.91)                           1.52 (0.79\~2.91)

   ≥ 60                       8977              87389.62              264                            302.10                       4.11 (2.44\~6.91)   4.36 (2.50\~7.61)                          4.34 (2.49\~7.58)                           4.34 (2.49\~7.58)

  Income (NTD)                                                                                                                                                                                                                               

   \< 15840                   7953              78218.91              194                            248.02                       1.00                1.00                                       1.00                                        1.00

   ≥ 15840\~\< 21900          1659              17303.76              59                             340.97                       1.42 (1.06\~1.89)   1.20 (0.89\~1.61)                          1.19 (0.89\~1.60)                           1.19 (0.89\~1.60)

   ≥ 21900\~\< 34800          3169              29896.16              47                             157.21                       0.62 (0.45\~0.85)   0.72 (0.52\~0.99)                          0.72 (0.52\~0.99)                           0.72 (0.52\~0.99)

   ≥ 34800                    905               8399.93               5                              59.52                        0.23 (0.10\~0.57)   0.49 (0.19\~1.25)                          0.49 (0.19\~1.24)                           0.49 (0.19\~1.24)

  ICS use                                                                                                                                                                                                                                    

   No ICS use                 12396             119953.57             283                            235.92                       1.00                1.00                                       1.00                                        

   Any ICS use                1290              13865.20              22                             158.67                       0.70 (0.46\~1.09)   0.71 (0.46\~1.10)                                                                      

    Cumulative dose (mg)                                                                                                                                                                                                                     

   \> 0 mg\~≤ 39.48 mg        668               6867.18               15                             218.43                       0.95 (0.67\~1.60)                                              0.96 (0.57\~1.61)                           

   \> 39.48 mg                622               6998.02               7                              100.03                       0.45 (0.21\~0.96)                                              0.46 (0.21\~0.97)                           

    dose-duration-day (DDD)                                                                                                                                                                                                                  

   \< 28 DDD                  12951             125631.79             296                            235.61                       1.00                                                                                                       1.00

   ≥ 28 DDD\~≤ 100 DDD        381               4154.89               5                              120.34                       0.54 (0.22\~1.30)                                                                                          0.53 (0.22\~1.29)

   \> 100 DDD                 354               4032.08               4                              99.20                        0.45 (0.17\~1.21)                                                                                          0.46 (0.17\~1.23)

  Medical disease                                                                                                                                                                                                                            

   Pulmonary tuberculosis                                                                                                                                                                                                                    

    Without                   12703             123583.93             248                            200.67                       1.00                1.00                                       1.00                                        1.00

    With                      983               10234.83              57                             556.92                       2.87 (2.15\~3.83)   2.65 (1.95\~3.59)                          2.65 (1.95\~3.60)                           2.66 (1.96\~3.60)

   Pneumonia                                                                                                                                                                                                                                 

    Without                   12525             121681.34             285                            234.22                       1.00                1.00                                       1.00                                        1.00

    With                      1161              12137.42              20                             164.78                       0.73 (0.46\~1.14)   0.54 (0.34\~0.86)                          0.54 (0.34\~0.86)                           1.29 (0.92\~1.80)

   Bronchiectasis                                                                                                                                                                                                                            

   Without ICD494             12416             119980.56             259                            215.87                       1.00                1.00                                       1.00                                        1.00

   With ICD494                1270              13838.20              46                             332.41                       1.63 (1.19\~2.23)   1.28 (0.91\~1.79)                          1.29 (0.92\~1.80)                           1.29 (0.92\~1.80)

   Pulmonary fibrosis                                                                                                                                                                                                                        

   Without                    13531             132174.84             298                            225.46                       1.00                1.00                                       1.00                                        1.00

   With                       155               1643.92               7                              425.81                       1.97 (0.93\~4.16)   1.38 (0.64\~2.98)                          1.36 (0.63\~2.94)                           1.36 (0.63\~2.92)

   Hypertension                                                                                                                                                                                                                              

   Without                    3460              31513.57              101                            320.50                       1.00                1.00                                       1.00                                        1.00

   With                       10226             102305.19             204                            199.40                       0.65 (0.51\~0.82)   0.59 (0.46\~0.75)                          0.59 (0.46\~0.75)                           0.59 (0.46\~0.75)

   Diabetes mellitus                                                                                                                                                                                                                         

   Without                    7624              71842.76              210                            292.31                       1.00                1.00                                       1.00                                        1.00

   With                       6062              61976.00              95                             153.29                       0.54 (0.43\~0.69)   0.58 (0.45\~0.74)                          0.58 (0.45\~0.74)                           0.58 (0.45\~0.74)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: NTD: New Taiwan Dollar.

![The cumulative lung cancer probability among ICS users (\> 39.48 mg) and nonusers\
Note: The cumulative lung cancer probability significantly decreased among the ICs users compared with nonusers (*P* = 0.0222). Abbreviation: ICS: inhaled corticosteroids.](oncotarget-08-29711-g002){#F2}

The relationship between risk of lung cancer and other variables {#s2_3}
----------------------------------------------------------------

Being elderly was associated with a higher risk of lung cancer, and age ≥ 60 years led to an increased risk (HR = 4.34 \[95% CI: 2.49--7.58\]). Median and high income (21900--34800 and ≥ 34800 NTD per month, respectively) were associated with a lower risk of lung cancer compared to low income, but this was not significant. Pneumonia \[multivariate-adjusted HR = 0.54 (95% CI: 0.34--0.96)\], diabetes mellitus \[multivariate-adjusted HR = 0.58 (95% CI: 0.45--0.74)\], and hypertension \[multivariate-adjusted HR = 0.59 (95% CI: 0.46--0.75)\] were all significantly associated with a reduced risk of lung cancer. Pulmonary tuberculosis (TB) was significantly associated with an increased risk of lung cancer \[HR = 2.65 (95% CI: 1.95--3.60)\]. Bronchiectasis and pulmonary fibrosis were not associated with lung cancer risk.

DISCUSSION {#s3}
==========

Our study demonstrated that ICS have a dose-dependent negative association with lung cancer risk, and that an ICS cumulative dose \> 39.48 mg is significantly associated with a lower risk for lung cancer after adjusting for age, income, and comorbidities. The time to lung cancer diagnosis after initial diagnosis of COPD in ICS users was significantly longer than in ICS non-users; thus, ICS may have a protective effect against lung cancer. To account for these observations, the following mechanisms were considered. First, chronic inflammation has been found to play a role in cancer pathogenesis in a number of COPD cases. COPD is accompanied by an enhanced chronic inflammatory response in the airways and lungs \[[@R1]\], and ICS has the effect of reducing airway, lung, and systemic inflammation in COPD patients \[[@R17]--[@R19]\]. Previous studies have demonstrated that inhaled budesonide can decrease the number of neutrophils, as well as the levels of IL-6, TNF-α, and IL-8 in bronchoalveolar lavage samples in COPD patients \[[@R28], [@R29]\]. Smokers with COPD who have been prescribed inhaled fluticasone treatment showed decreased CD8/CD4 ratios and subendothelial mast cells in airway biopsies compared to patients using placebo \[[@R18]\]. ICS could also reduce C-reactive protein levels in COPD patients compared to other treatment regimens \[[@R30]\]. Inflammatory markers have also been found to increase during COPD exacerbations. Regular ICS treatments have reduced exacerbations in COPD patients \[[@R31]\], and withdrawal from ICS treatment has led to exacerbations in some patients \[[@R32]\]. The decrease in acute COPD exacerbations through ICS treatment reduces airway and systemic inflammation, thereby indirectly decreasing lung cancer incidence. Second, cyclooxygenase and prostaglandins have a major impact on lung tumor progression and tumor-associated inflammation. ICS may suppress proto-oncogenes in human smokers via modulating the COX-2 inflammatory pathway \[[@R15]\]. COX-2 is overexpressed in most non-small cell lung cancers (NSCLCs). COX-2 induced-prostaglandin E2 has been shown to be involved in anti-apoptosis, angiogenesis, tumor invasion, and inhibition of antitumor immunity. Therefore, COX-2 inhibitors have been applied to suppress the development and progression of lung cancer. Glucocorticoids are the most potent COX-2 inhibitors; they function by suppressing COX-2 expression through stimulating the glucocorticoid receptor (GR) \[[@R33]--[@R35]\] and reducing prostaglandin production through inhibition of cytosolic phospholipase A2 activity \[[@R36]\]. Third, ICS themselves may mediate a protective effect against lung cancer. *In vitro* studies have demonstrated that glucocorticoids have growth-inhibitory effects on NSCLC cell lines. Dexamethasone has been shown to exhibit growth-inhibitory effects on several GR-rich NSCLC cell lines \[[@R37]\]. Dexamethasone and budesonide have been shown to inhibit the proliferation of A549 cells, a GR-rich adenocarcinoma-derived human alveolar epithelial cell line \[[@R38], [@R39]\]. Budesonide has been shown to have chemopreventive efficacy on mouse lung tumorigenesis by modulating p53 and BclII protein expression \[[@R16]\]. Additionally, adrenalectomies have been demonstrated to enhance lung tumor formation in mouse models.

Raymakers et al. obtained several conflicting results about ICS effects on lung cancer in a systematic review. Their analysis of randomized controlled trials (RCTs) showed no statistically significant association between ICS use and lung cancer risk, whereas observational studies showed a protective effect of ICS use, particularly at higher doses and with more frequent use \[[@R27]\]. The primary objective of these RCTs was not to examine the protective effects of ICS on lung cancer, but the efficacy of ICS use in COPD. Low numbers of lung cancer events in the ICS treatment group and the controls were found in these RCTs during a short study period. It is possible that ICS do not protect against lung cancer in such a short follow-up time. Additionally, two observational studies showed a median time from COPD diagnosis to lung cancer of 2.2 and 1.4 years. Cancer latency periods tend to be quite long; thus, it must be considered that patients included in this study may have already had latent cancer. The time to lung cancer diagnosis after an initial diagnosis of COPD in our study population was significantly different between ICS users and non-users (10.75 vs. 9.68 years, *P \<* 0.001).

The strengths of our study included its use of national population-based data that are highly representative of the general population. Our study had larger numbers (13,686 COPD patients) and a longer duration (the median follow-up period 9.78 years) than previous studies, which allowed for more data on COPD patients. When or whether a patient is prescribed ICS is decided by the physician according to COPD severity development, introducing another real world condition.

Additionally, our study also showed that age ≥ 60 years, pneumonia, diabetes mellitus, and hypertension were significantly associated with reduced risk of lung cancer, whereas pulmonary TB was associated with a higher risk of lung cancer.

Diabetic patients with COPD had a lower incidence of lung cancer than non-diabetic COPD patients. This requires further study to clarify whether this effect was due to diabetes itself or the antidiabetic medication. The literature shows that metformin and thiazolidinedione can reduce the incidence of lung cancer in patients with type 2 diabetes \[[@R41]--[@R44]\], but diabetes itself has no effect on the incidence of lung cancer \[[@R44]\]. This mechanism is due to the systemic effect of metformin in reducing the circulating level of insulin and insulin-like growth factor-1, which may associated with anticancer action \[[@R45]\]. Our study demonstrated that hypertension was associated with reduced lung cancer risk. β blockers \[[@R46]--[@R51]\] and captopril \[[@R51]\] are considered potential inhibitors of lung tumor growth and metastasis. β blockers may lower the risk of NSCLC development among smokers, and may be used to enhance the clinical outcome of standard cancer therapies. The antitumorigenic mechanisms of β blockers may be because of the inhibition or blockage of norepinephrine\[[@R46], [@R47]\] and nicotine effects \[[@R46]\], or inhibition of a beta-adrenergic receptor-mediated mitogenic pathway \[[@R49]\]. Treatment of LNM35 lung cancer cells with captopril was found to induce apoptosis \[[@R51]\].

This study showed that pulmonary TB in COPD patients increased the incidence of lung cancer, which is consistent with findings of previous reports \[[@R52]--[@R55]\]. Pulmonary TB may be associated with an increased risk of all major subtypes of lung cancer \[[@R52], [@R53], [@R55]\]; frequent x-ray exposure and chronic lung inflammation may be the mechanisms for lung cancer development \[[@R52]--[@R54]\]. Pneumonia was associated with reduced lung cancer risk in our study, which is consistent with previous studies \[[@R56]\]. However, there have been conflicting results \[[@R54]\]. The protective effect of pneumonia on lung cancer may reflect potential differences in immune responses, and further investigation is needed to confirm this.

Our results showed that treatment with ICS resulted in decreased lung cancer incidence. It also reduces the frequency of COPD exacerbations and improves quality of life. However, long-term high-dose ICS may have some deleterious effects, such as oral candidiasis, hoarse voice, skin bruises, pneumonia \[[@R57], [@R58]\], and pulmonary TB \[[@R59]\]. Triamcinolone Acetonide is associated with reduced bone density. Physicians should carefully weigh the potential risks, benefits, and costs associated with the use of ICS in individuals with COPD.

There were a number of important limitations associated with our study. First, we used ICD-9 diagnostic codes to enroll the patients; thus, we were unable to confirm COPD diagnosis by spirometry or differentiate severity by FEV1. Lung cancer may be related to COPD severity. However, many debates exist on the evaluation of COPD severity. The updated guidelines indicate that the evaluation of COPD severity needs a multidimensional approach. BODE (body mass index, airflow obstruction, dyspnea, and exercise capacity) score, comorbidities, and fibrinogen or CRP biomarkers are also considered important factors for COPD severity. Thus, multidimensional data collection is not easily done, even in a prospective study. In addition, ICS use is suggested in patients with severe and very severe COPD, according to GOLD guidelines. In theory, patients with severe and very severe COPD have a higher incidence of lung cancer than patients with mild and moderate COPD. However, our results show that patients with more severe COPD using ICS are less likely to have lung cancer, which further indicates that ICS reduced the incidence of lung cancer in COPD patients. Second, our study is a population-based cohort study. When or whether a patient starts to use ICS is decided by the physician. This eliminates interference by COPD stage and severity at initial enrollment. Third, the NHI database used to enroll the patients did not allow us to differentiate between squamous cell carcinoma and non-squamous cell carcinoma, despite the epidemiology and carcinogenic process being quite different between lung cancer subtypes. Fourth, we have concerns regarding medication adherence. Patients pay a part of all medical expenses under Taiwan\'s current health-care system. It is not logical that these patients would see a doctor regularly and not take prescribed medicines, yet still be willing to pay for long-term medical costs. Thus, we believe that, although we calculated ICS dose based on NHI records that cannot show the dose that the patients actually received, the difference should be very limited. Another important limitation of the study is the lack of our NHI data for important risk factors, e.g., detailed patient history of tobacco use, symptoms, diet conditions and occupational exposures.

In conclusion, this nationwide population-based cohort study with a 15-year duration and larger population adds positive evidences that ICS have a potential role in lung cancer prevention among female patients with COPD. However, a stronger prospective study design and data replications are necessary to validate our findings.

MATERIALS AND METHODS {#s4}
=====================

Source of data {#s4_1}
--------------

The NHI Program, which provides compulsory universal health insurance in Taiwan, was implemented March 1, 1995. Since then, 98% of the island\'s population receives all forms of health care services, including outpatient services, inpatient care, Chinese medicine, dental care, childbirth services, physical therapy, preventive health care, home care, and rehabilitation for chronic mental illness through this program. Most medical providers (93%) are under contract with the Bureau of NHI (BNHI), and those that are not under contract provide fewer health services. Consequently, more than 96% of Taiwan\'s population has insurance coverage through the NHI and has utilized health services at least once at contracted medical institutions. Based on the availability of the reimbursement claim records under a single payer system, a systematic sampling method was used by the National Health Research Institute (NHRI) of Taiwan to establish a randomly sampled and representative panel database of 1,000,000 patients. This database was established in 2000 for research purposes, and the NHRI has reported that there are no statistically significant differences in age, gender, and health care costs between the sample group and all enrollees \[[@R60]\].

Data regarding daily clinic visits and hospital admissions are available in an electronic format and can be obtained for each contracted medical institution. In order to be reimbursed, all medical institutions must submit their claims for billable medical services on a standardized electronic form, and this form includes data elements such as the date of admission and discharge, patient identification number, gender, birthday, and ICD-9-CM diagnostic code for each admission. Therefore, the information from the NHI database appears to be sufficiently complete, reliable, and accurate for use in epidemiological studies. This study was approved by the Institutional Review Board at the Chang-Gung Memorial Hospital (IRB \#102-0364B). The requirement for informed consent was waived as the personal information used had already been de-identified in the NHI Research Database.

Study design and participants {#s4_2}
-----------------------------

The worldwide average incidence of lung cancer in men is approximately 3-fold higher than that in women \[[@R61]\]. Taiwan has a particularly high male smoking prevalence, and but the prevalence in women is much lower. The ratio of male to female smoking rates is 10.9 to 1 among adults (46.8%/4.3%) in Taiwan \[[@R62]\], and about 15--20% of these female smokers may acquire COPD. Data about tobacco consumption and second-hand exposure could not be obtained from BNHI records. Therefore, to decrease the interference of sex and tobacco exposure in the incidence of lung cancer, we decided to select only female patients in this study. We identified an exposed study cohort from the database consisting of female patients newly diagnosed with COPD from 1996 to 2011. Patients were defined by the presence of two or more diagnostic codes for COPD (International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) 491, 492, 496) within 12 months in either inpatient or outpatient service claims submitted between 1996 and 2011 (*n* = 88,513). Patients were excluded if they were younger than 40 years, if lung cancer had been diagnosed prior to the diagnosis of COPD, or the patient had cases of asthma (ICD-9 CM code 493.X) before the index date. The index date for each participant was the date of first COPD diagnosis. A flowchart describing this process is shown in Figure [1](#F1){ref-type="fig"}. Potential confounders including age \[[@R63]\], income \[[@R64]\], and comorbidities such as pulmonary TB \[[@R52]--[@R55]\], pneumonia \[[@R54], [@R56]\], bronchiectasis \[[@R65]\], pulmonary fibrosis \[[@R66]\], hypertension \[[@R46]--[@R51]\], and diabetes \[[@R41]--[@R45]\] have been reported to be associated with lung cancer risk. Therefore, these factors were also included in this study.

Exposure assessment {#s4_3}
-------------------

The ICS that were analyzed in this study included fluticasone propionate and budesonide. Information regarding exposure to ICS was extracted from the prescription database. Users of ICS were defined as those who received at least one prescription for an ICS between the COPD diagnosis date and index date. The date of prescription, daily dose, and number of days supplied were identified and cumulative doses (mg) were calculated. The use of ICS was approved in Taiwan in June 2001 and was placed on the listing of NHI drugs for reimbursement in February 2002. The period of an ICS prescription at 1 visit is at most 28 days in Taiwan. Therefore, ICS users were defined as patients who received an ICS prescription for \> 28 days, and those who did not receive an ICS prescription were classified as nonusers of ICS. To evaluate the exposure effects of ICS, ICS dose-duration-day (DDD) according to WHO suggestion was cumulatively calculated as days of ICS prescription. (<https://www.whocc.no/atc_ddd_index/>)

Lung cancer outcome and patient follow-up {#s4_4}
-----------------------------------------

The index date for each participant was the first date of COPD diagnosis. The study endpoint was established based on the first diagnosis of lung cancer (ICD-9 162.X) from outpatient claims or hospitalization records from 1997 to 2011. All of the study participants were followed from the index date to endpoint occurrence, withdrawal from the database, or the end of 2011, whichever came first.

Statistical analysis {#s4_5}
--------------------

The person-years of follow-up for each case were calculated from the date of COPD diagnosis to the date of death or December 31, 2011. Incident rates were calculated by dividing the number of deaths from lung cancer by the number of person-years of follow-up. Model I was Cox regression analysis of relative risk of lung cancer incidence adjusted by age, income, and comorbidities and any ICS use. Model II was Cox regression analysis of relative risk of lung cancer incidence adjusted by age, income, and comorbidities and ICS cumulative dose. The participants were divided into three exposure categories: ICS non-users, ICS users of doses equal to or less than the median, and ICS users of doses greater than the median (median based on the distribution of use among all ICS cases). Hazard ratios and their 95% confidence intervals were calculated with non-user patients as a reference. To test the dosage effects of ICS, we further performed model III Cox regression analysis adjusted by tertiles of ICS DDD, by age, income, and comorbidities. ICS use was divided into tertiles by the DDD, and nonusers of ICS (\< 28 DDD) were the reference point. Analyses were performed using the SAS statistical package (version 9.3; SAS Institute Inc., Cary, NC, USA). All statistical tests were two-sided and a *P-value* \< 0.05 was considered statistically significant.
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COPD

:   chronic obstructive pulmonary disease

ICS

:   inhaled corticosteroids

CI

:   confidence interval

HR

:   hazard ratio

IRB

:   institutional review board

NHI

:   National Health Insurance

NHRI

:   National Health Research Institute

ICD-9-CM

:   International Classification of Diseases, Ninth Revision- Clinical Modification

BNHI

:   Bureau of National Health Insurance

COX-2

:   cyclooxygenase-2

CRP

:   C-reactive protein

GOLD

:   Global Initiative for Chronic Obstructive Pulmonary Disease

NSCLC

:   non-small cell lung cancer

TB

:   tuberculosis

GR

:   glucocorticoid receptor

NTD

:   New Taiwan Dollar

BODE

:   body mass index, airflow obstruction, dyspnea, and exercise capacity

FEV1

:   a forced expiratory volume in the first second

DDD

:   dose-duration-day
